Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Delayed Swiss Exchange  -  11:31 2022-09-28 am EDT
82.30 CHF   -4.08%
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution
EQ
09/09Transcript : Medacta Group SA, H1 2022 Earnings Call, Sep 09, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta Group SA publishes 2022 Annual General Meeting invitation

04/22/2022 | 01:02am EDT

Medacta Group SA / Key word(s): AGMEGM
Medacta Group SA publishes 2022 Annual General Meeting invitation

22.04.2022 / 07:00


Media Release

Medacta Group SA publishes 2022 Annual General Meeting invitation

CASTEL SAN PIETRO, 22 April 2022 - Medacta Group SA ("Medacta", SIX:MOVE) published today the invitation to the Annual General Meeting ("AGM") which will take place on 19 May 2022 at the headquarters in Castel San Pietro, Switzerland, without physical attendance due to the uncertainties in connection with the coronavirus and after giving priority to well-being and safety of our Shareholders.

Shareholders will be able to vote their shares by giving a power of attorney and related voting instructions to the independent proxy, either by returning the proxy form or by exercising their voting rights online.

Shareholders will be given the opportunity to submit questions to the Board of Directors on Agenda Items via email to investor.relations@medacta.ch by May 13, 2022.

The Board of Directors is proposing to the AGM the distribution of CHF 10.7 million or CHF 0.535 per share, half of it to be distributed as dividend out of available earnings and half of it to be distributed out of accumulated reserves from capital contribution.

The Board is proposing the re-election of Dr. Alberto Siccardi as Chairman of the Board of Directors. All current board members stand for re-election.

The Board is also proposing the re-election of the members of the Remuneration Committee and the approval of the maximum amount of compensations for the members of the Board of Directors and the Group Executive Management. Further motions include the re-election of the Independent Proxy Holder and Auditors for the financial year 2022.

All details on the motions can be found in the invitation to the 2022 AGM at https://www.medacta.com/EN/agm.

Contact
Medacta International SA
Gianna La Rana, Head of Investor Relations
Phone: +41 91 696 14 95
investor.relations@medacta.ch


About Medacta
Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.



End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1332281

 
End of News EQS News Service

1332281  22.04.2022 

fncls.ssp?fn=show_t_gif&application_id=1332281&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about MEDACTA GROUP SA
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and..
EQ
09/09Transcript : Medacta Group SA, H1 2022 Earnings Call, Sep 09, 2022
CI
09/09Swiss Orthopedic Group Medacta Lifts FY22 Outlook as H1 Revenue Grows; Profit Slows
MT
09/09Medacta : 2022 Half-Year Report
PU
09/09Medacta : 2022 Half-Year Presentation
PU
09/09Medacta Group SA reports strong revenue growth of 19.0% and adjusted EBITDA margin of 2..
EQ
09/09Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022
CI
09/08Medacta Group SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/29Transcript : Medacta Group SA, H1 2022 Earnings Call, Jul 29, 2022
CI
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 428 M 413 M 413 M
Net income 2022 55,8 M 53,8 M 53,8 M
Net Debt 2022 137 M 133 M 133 M
P/E ratio 2022 30,8x
Yield 2022 0,72%
Capitalization 1 740 M 1 678 M 1 678 M
EV / Sales 2022 4,38x
EV / Sales 2023 3,79x
Nbr of Employees 1 421
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 87,09 €
Average target price 110,94 €
Spread / Average Target 27,4%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-39.58%1 731